stilbenes and hemiasterlin

stilbenes has been researched along with hemiasterlin* in 3 studies

Other Studies

3 other study(ies) available for stilbenes and hemiasterlin

ArticleYear
A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approach.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Aug-25, Volume: 91

    We report the design, synthesis and biological characterisation of a novel hybrid drug by conjugation of two tubulin inhibitors, a hemiasterlin derivative A (H-Mpa-Tle-Aha-OH), obtained by condensation of three non-natural amino acids, and cis-3,4',5-trimethoxy-3'aminostilbene (B). As we have previously demonstrated synergy between A and B, we used a monocarbonyl derivative of triethylene glycol as linker (L) to synthesise compounds A-L and A-L-B; via HPLC we analysed the release of its potential hydrolysis products A, A-L, B and B-L in physiological fluids: the hybrid A-L-B undergo hydrolysis in rat whole blood of the ester bond between A and L (half-life=118.2±9.5min) but not the carbamate bond between B and L; the hydrolysis product B-L was further hydrolyzed, but with a slower rate (half-life=288±12min). The compound A-L was the faster hydrolyzed conjugate (half-life=25.4±1.1min). The inhibitory activity of the compounds against SKOV3 ovarian cancer cell growth was analysed. The IC50 values were 7.48±1.27nM for A, 40.3±6.28nM for B, 738±38.5nM for A-L and 37.9±2.11nM for A-L-B. The anticancer effect of A-L-B was evidenced to be obtained via microtubule dynamics suppression. Finally, we stated the expression of the active efflux transporters P-gp (ABCB1) and MRP1 (ABCC1) in the human normal colon epithelial NCM460 cell line by reverse-transcription PCR. Via permeation studies across NCM460 monolayers we demonstrate the poor aptitude of A to interact with active efflux transporters (AET): indeed, the ratio between its permeability coefficients for the basolateral (B)→apical (A) and B→A transport was 1.5±0.1, near to the ratio of taltobulin (1.12±0.06), an hemiasterlin derivative able to elude AETs, and significantly different form the ratio of celiprolol (3.4±0.2), an AET substrate.

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Cycle; Cell Line; Cell Line, Tumor; Drug Stability; Humans; Hydrolysis; Liver; Male; Multidrug Resistance-Associated Proteins; Oligopeptides; Rats, Wistar; Solubility; Stilbenes; Tubulin Modulators

2016
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Hemiasterlins are cytotoxic tripeptides with antimicrotubule activity originally isolated from marine sponges. We have developed new hemiasterlin derivatives BF65 and BF78 that are highly potent to induce cancer cell death in the low nanomolar range. Examination of their mechanisms of cell cycle arrest and disruption of microtubules revealed an unusual characteristic in addition to anti-tubulin effect. Immunofluorescence staining revealed that A549 lung carcinoma cells treated with BF65 or BF78 exhibited both monopolar and multipolar mitotic spindles. Centrosomes were separated with short spindle microtubules in cells with multipolar spindles. In vitro tubulin polymerization assay confirmed that both BF65 and BF78 were highly potent to inhibit tubulin polymerization. These two compounds induced the formation of monoastral spindles suggesting that they might be inhibitors of mitotic kinesins such as KSP/Eg5. However, kinetic measurement of microtubule activated kinesin ATPase activity demonstrated that unlike the positive control monastrol, neither BF65 nor BF78 suppressed KSP/Eg5 activity. Hence the effect may be a variant form of tubulin inhibition. Similar to vinca alkaloids, BF compounds synergized with a colchicine site microtubule inhibitor stilbene 5c both in vitro and in vivo, which may provide a potential drug combination in the future clinical application.

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Drug Synergism; Fluorescent Antibody Technique; Humans; Kinesins; Mice; Microtubules; Oligopeptides; Polymerization; Signal Transduction; Spindle Apparatus; Stilbenes; Treatment Outcome; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays

2012
Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives.
    Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9

    A series of tubulysin analogs in which one of the stereogenic centers of tubuphenylalanine was eliminated were synthesized. All compounds were tested for antiproliferative activity towards ovarian cancer cells and for inhibition of tubulin polymerization. The dimethyl analogs were generally more active than the desmethyl analogs, and four analogs have tubulin polymerization IC(50) values similar to combretastatin A4 and the hemiasterlin analog HTI-286.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; Humans; Inhibitory Concentration 50; Models, Chemical; Oligopeptides; Ovarian Neoplasms; Phenylalanine; Stilbenes; Structure-Activity Relationship; Tubulin Modulators

2008